secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001628280-24-013295
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI reports Q4 revenue $86M (+20.1% YoY), net loss widens to $18.8M
-------------------------------------------------------------------

- Q4 2023 revenue $86M (+20.1% YoY); gross profit $14M (-8.0% YoY).
- Net loss $18.8M (vs $11.0M loss in Q4 2022); diluted EPS -$0.21.
- Adjusted EBITDA -$6.3M (vs -$4.6M in prior year quarter).
- Operational: remediated material weakness, signed full-risk contract in South Florida, launched CA pharmacy with 1,300 specialty fills.
- Ended 2023 with 69 clinics, 119 providers; cash $83M. 2024 outlook mentioned but not detailed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000162828024013295/0001628280-24-013295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000162828024013295/toi-20240327.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-013295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer